← Back to Search

Janus Kinase (JAK) Inhibitor

Ruxolitinib cream for Vitiligo

Phase 2
Waitlist Available
Research Sponsored by Incyte Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from the completion of the week 24 assessments until at least 30 days after the last application of study drug at week 52 + 30 days
Awards & highlights

Study Summary

This trial will study how well ruxolitinib cream works to treat vitiligo by measuring changes in biomarkers.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from the time of informed consent form signing until at least 30 days after the last application of study drug (up to week 24 + 30 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from the time of informed consent form signing until at least 30 days after the last application of study drug (up to week 24 + 30 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage Change From Baseline in Chemokine (C-X-C Motif) Ligand 10 (CXCL10), an Immune Biomarker, at Week 4, Week 12, and Week 24
Secondary outcome measures
Correlation of Key Skin Inflammatory Biomarkers of Vitiligo in Target Lesions to Efficacy Readouts
Number of Participants With TEAEs During the Treatment-Extension Period
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Ruxolitinib creamExperimental Treatment1 Intervention
Ruxolitinib cream will be administered twice a day (BID) for 24 weeks
Group II: Vehicle CreamPlacebo Group1 Intervention
Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ruxolitinib cream
2022
Completed Phase 3
~1850

Find a Location

Who is running the clinical trial?

Incyte CorporationLead Sponsor
364 Previous Clinical Trials
55,087 Total Patients Enrolled
9 Trials studying Vitiligo
2,452 Patients Enrolled for Vitiligo

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What medical issues is Ruxolitinib cream commonly used to address?

"Ruxolitinib cream is the preferred treatment for polycythemia vera. Other conditions it may be prescribed to manage include hydroxyurea-resistant or -intolerant polycythemia, as well as primary myelofibrosis."

Answered by AI

What is the aggregate number of individuals partaking in this clinical experiment?

"Unfortunately, this trial has ceased to accept new participants. The initial posting was on June 23rd 2021 and the final update happened on September 14th 2022. However, if one is interested in similar trials there are 37 vitiligo studies recruiting now and 97 for Ruxolitinib cream which remain open."

Answered by AI

Is there still an opportunity for participants to join this research endeavor?

"Unfortunately, this clinical trial is not presently enrolling participants. It was first published on June 23rd 2021 and updated most recently on September 14th 2022. On the other hand, if you are still seeking a medical trial to participate in, there are currently 37 studies accepting vitiligo patients and 97 recruiting for Ruxolitinib cream."

Answered by AI

What is the current extent of this clinical trial's implementation in hospitals?

"Eleven medical centres are involved in this trial, such as First Oc Dermatology located in Fountain Valley, UC Irvine situated at Irvine, and JRB Research Inc found in Ottawa. The other eight sites have yet to be revealed."

Answered by AI

Are there any analogous research endeavors concerning Ruxolitinib cream?

"First studied in 2002 at the NIH Clinical Center, ruxolitinib cream has been subject to 110 clinical trials. Currently 97 of these studies are ongoing with a significant number occurring out of Fountain Valley, California."

Answered by AI

What potential harms may arise from using Ruxolitinib cream?

"Our assessment of the safety of Ruxolitinib cream was a 2, as it is still in Phase 2 and thus there are some data points that support its security but none that suggest efficacy."

Answered by AI

Who else is applying?

What state do they live in?
Ontario
New York
Virginia
Other
How old are they?
65+
18 - 65
What site did they apply to?
First Oc Dermatology
UC Irvine
George Washington Medical Faculty Associates
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
0
1

Why did patients apply to this trial?

interested in trying this drug and DC is fairly close to me.
PatientReceived 1 prior treatment

How responsive is this trial?

Average response time
  • < 2 Days
Most responsive sites:
  1. Mount Sinai Hospital: < 48 hours
Typically responds via
Phone Call
~16 spots leftby Apr 2025